First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early bre

[News]

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

More...

Hi, my name is Carole D and I have breast cancer, HER2, had my mastectomy Feb 3, 08.
I am now receiving Herceptin, every 3 weeks. Thus far, haven't had any serious reaction, other than fatigue and chillness. Would like to talk to others who are experiencing the same treatment.

I am 72, in fact just had my birthday on May l7th. It has been a difficult 6 months, but am finally coping with it.

Thank you.

Carole